National Research Program
Decades of research have improved survival rates and treatment for people with leukaemia, lymphoma, myeloma and related blood disorders. However, blood cancer remains the second biggest cause of cancer death in Australia. Some forms of leukaemia have five year survival rates as low as 38 per cent.
The Leukaemia Foundation's National Research Program funds vital research into the causes, epidemiology, diagnosis and treatment, psychosocial impact, management and cures of blood cancers and related disorders. In 2011 we will invest $4.3 million dollars, making our total investment over $20 million since 2005.
"In 2011 the Leukaemia Foundation is proud to announce a significant increase in our total research investment to $4.3 million. This includes funding 31 new projects as well as 28 continuing grants. We are excited by the potential for scientific and medical discovery that these grants represent."
Leukaemia Foundation CEO
In addition to our National Research Program, we provide ongoing funding to the prestigious Leukaemia Foundation Research Unit at Queensland Institute of Medical Research and to the national Australasian Leukaemia and Lymphoma Group Tissue Bank at the Princess Alexandra Hospital, Brisbane. We provide funding to support clinical trials in conjunction with the ALLG to directly assist in development of better treatments for patients. Recently we have entered into a strategic partnership with Cancer Australia to fund priority-driven research from 2010.
The Leukaemia Foundation is committed to growing our National Research Program and to encouraging innovative Australian research.
"Australian medical researchers have an outstanding history of major advances in the area of blood and bone marrow cancers over the last 50 years. Much more needs to be done to build on this proud tradition. A vital part of the Vision of the Leukaemia Foundation is to foster and support dedicated and creative young Australian scientists and doctors in continuing to make important scientific discoveries, that will ultimately contribute to the cure of patients with these serious diseases."
Professor Ken Bradstock
Chair, Medical and Scientific Advisory Committee